RxDoctor Payments Data

Jeanne Morris-Foley

Nurse Practitioner · Port Jefferson Station, NYNPI 1437189925

Payments from drug & device makers

$2,670in general payments, 2019–2025

Across 99 payments — averaging $26.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • AbbVie$429
  • Otsuka America Pharmaceutical, Inc.$328
  • Lundbeck LLC$282
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$258
  • Corium, LLC$117
  • plus $155 from 3 others

What the payments were for

  • Food & beverage$2,62398%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,670 in reported general payments places this provider in the 90th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$131,141
Medicare patients
73
Services billed
1,283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZoloftSertraline Hcl13$10,657
TrintellixVortioxetine Hydrobromide14$7,799
Duloxetine Hcl88$4,076
Fluoxetine Hcl100$2,165
Alprazolam182$1,735
Aripiprazole19$1,498
Escitalopram Oxalate118$1,010
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine29$971
Mirtazapine53$891
Trazodone Hcl19$658
Bupropion XlBupropion Hcl36$566
Quetiapine Fumarate22$518
Clonazepam119$511
Perphenazine12$474
Venlafaxine Hcl ErVenlafaxine Hcl36$451

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$1,102$7,79914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Port Jefferson Station

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →